Therapeutic targeting of replicative immortality

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages S104-S128

  Yaswen, Paul ^a   MacKenzie, Karen L ^b   Keith, W Nicol ^c   Hentosh, Patricia ^d   Rodier, Francis ^e   Zhu, Jiyue ^f   Firestone, Gary L ^g   Matheu, Ander ^h   Carnero, Amancio ⁱ   Bilsland, Alan ^c   Sundin, Tabetha ^j   Honoki, Kanya ^k   Fujii, Hiromasa ^k   Georgakilas, Alexandros G ^l   Amedei, Amedeo ^m   Amin, Amr ^n,o   Helferich, Bill ^p   Boosani, Chandra S ^q   Guha, Gunjan ^r   Ciriolo, Maria Rosa ^s   Chen, Sophie ^t   Mohammed, Sulma I ^u   Azmi, Asfar S ^v   Bhakta, Dipita ^r   Halicka, Dorota ^w   Niccolai, Elena ^m   Aquilano, Katia ^s   Ashraf, S Salman ^n,o   Nowsheen, Somaira ^x   Yang, Xujuan ^p   more..

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d OLD DOMINION UNIVERSITY   (United States)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f WASHINGTON STATE UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

ⁱ UNIVERSITY OF SEVILLE   (Spain)

^j SENTARA HEALTHCARE   (United States)

^k NARA MEDICAL UNIVERSITY   (Japan)

^l NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^m UNIVERSITY OF FLORENCE   (Italy)

ⁿ UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^o CAIRO UNIVERSITY   (Egypt)

^p UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^q CREIGHTON UNIVERSITY   (United States)

^r SASTRA UNIVERSITY   (India)

^s UNIVERSITY OF ROME TOR VERGATA   (Italy)

^t Ovarian and Prostate Cancer Research Trust Laboratory   (United Kingdom)

^u PURDUE UNIVERSITY   (United States)

^v WAYNE STATE UNIVERSITY   (United States)

^w NEW YORK MEDICAL COLLEGE   (United States)

^x MAYO CLINIC   (United States)

more..

Author keywords

Oncogenic stress; P53; PRB; Senescence; Telomerase

Indexed keywords

3 INDOLEMETHANOL; ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; CURCUMIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DINACICLIB; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; FISETIN; FLUOROURACIL; GEMCITABINE; GENISTEIN; IMETELSTAT; PALBOCICLIB; PERILLYL ALCOHOL; PROTEIN P16; PROTEIN P53; RESVERATROL; RETINOBLASTOMA PROTEIN; SENESCENCE ASSOCIATED BETA GALACTOSIDASE; SMALL INTERFERING RNA; TELOMERASE; TELOMERASE INHIBITOR; TELOMERASE REVERSE TRANSCRIPTASE; TELOMESTATIN; TERTOMOTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE;

BREAST CANCER; BREAST METASTASIS; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RESISTANCE; CELL CYCLE ARREST; CENTRAL NERVOUS SYSTEM TUMOR; DNA DAMAGE; DRUG POTENTIATION; DRUG TARGETING; GENOMIC INSTABILITY; GLIOMA; HEMATOLOGIC DISEASE; HETEROCHROMATIN; HUMAN; HYPOPHYSIS TUMOR; LIVER CANCER; LUNG ADENOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; MULTIPLE MYELOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; PANCREAS CANCER; PARACRINE SIGNALING; PROSTATE CANCER; PROSTATE TUMOR; REVIEW; SENESCENCE; SOLID TUMOR; T CELL LYMPHOMA; TELOMERE; TELOMERE SHORTENING; THROMBOTIC THROMBOCYTOPENIC PURPURA; TUMOR ESCAPE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; CELL AGING; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFECTS; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL AGING; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; TELOMERASE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84926657997     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.03.007     Document Type: Review

References (567)

1. Wright W.E., Shay J.W. Time, telomeres and tumors: is cellular senescence more than an anticancer mechanism. Trends Cell Biol 1995, 5:293-297.
2. Kipling D., Wynford-Thomas D., Jones C.J., Akbar A., Aspinall R., Bacchetti S., et al. Telomere-dependent senescence. Nat Biotechnol 1999, 17:313-314.
3. Bilsland A.E., Cairney C.J., Keith W.N. Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives. J Cell Mol Med 2011, 15:179-186.
4. Morin G.B. The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 1989, 59:521-529.
5. Lingner J., Hughes T.R., Shevchenko A., Mann M., Lundblad V., Cech T.R. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science 1997, 276:561-567.
6. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
7. Harrington L., McPhail T., Mar V., Zhou W., Oulton R., Bass M.B., et al. A mammalian telomerase-associated protein. Science 1997, 275:973-977.
8. Shippen-Lentz D., Blackburn E.H. Functional evidence for an RNA template in telomerase. Science 1990, 247:546-552.
9. Blasco M.A., Funk W., Villeponteau B., Greider C.W. Functional characterization and developmental regulation of mouse telomerase RNA. Science 1995, 269:1267-1270.
10. Collins K. Mammalian telomeres and telomerase. Curr Opin Cell Biol 2000, 12:378-383.
11. Venteicher A.S., Abreu E.B., Meng Z., McCann K.E., Terns R.M., Veenstra T.D., et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science 2009, 323:644-648.
12. Cohen S.B., Graham M.E., Lovrecz G.O., Bache N., Robinson P.J., Reddel R.R. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315:1850-1853.
13. Cao Y., Bryan T.M., Reddel R.R. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. Cancer Sci 2008, 99:1092-1099.
14. Cristofari G., Lingner J. Telomere length homeostasis requires that telomerase levels are limiting. EMBO J 2006, 25:565-574.
15. Napier C.E., Veas L.A., Kan C.Y., Taylor L.M., Yuan J., Wen V.W., et al. Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells. Biochim Biophys Acta 2010, 1803:1142-1153.
16. Chiang Y.J., Hemann M.T., Hathcock K.S., Tessarollo L., Feigenbaum L., Hahn W.C., et al. Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol 2004, 24:7024-7031.
17. Keith W.N., Bilsland A., Hardie M., Evans T.R. Drug insight: cancer cell immortality-telomerase as a target for novel cancer gene therapies. Nat Clin Pract Oncol 2004, 1:88-96.
18. Cairney C.J., Keith W.N. Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 2008, 90:13-23.
19. Wright W.E., Piatyszek M.A., Rainey W.E., Byrd W., Shay J.W. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet 1996, 18:173-179.
20. Jia W., Wang S., Horner J.W., Wang N., Wang H., Gunther E.J., et al. A BAC transgenic reporter recapitulates in vivo regulation of human telomerase reverse transcriptase in development and tumorigenesis. FASEB J 2011, 25:979-989.
21. Wang S., Hu C., Zhu J. Transcriptional silencing of a novel hTERT reporter locus during in vitro differentiation of mouse embryonic stem cells. Mol Biol Cell 2007, 18:669-677.
22. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015. [see comments].
23. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., et al. Telomerase maintains telomere structure in normal human cells. Cell 2003, 114:241-253.
24. Yasumoto S., Kunimura C., Kikuchi K., Tahara H., Ohji H., Yamamoto H., et al. Telomerase activity in normal human epithelial cells. Oncogene 1996, 13:433-439.
25. Weng N.P., Levine B.L., June C.H., Hodes R.J. Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 1996, 183:2471-2479.
26. Chiu C.P., Dragowska W., Kim N.W., Vaziri H., Yui J., Thomas T.E., et al. Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells 1996, 14:239-248.
27. Engelhardt M., Kumar R., Albanell J., Pettengell R., Han W., Moore M.A.S. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood 1997, 90:182-193.
28. Suram A., Kaplunov J., Patel P.L., Ruan H., Cerutti A., Boccardi V., et al. Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J 2012, 31:2839-2851.
29. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.-P., Morin G.B., et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998, 279:349-352.
30. Counter C.M., Hahn W.C., Wei W., Caddle S.D., Beijersbergen R.L., Lansdorp P.M., et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. Proc Natl Acad Sci U S A 1998, 95:14723-14728.
31. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumor cells with defined genetic elements. Nature 1999, 400:464-468.
32. Zhu J., Wang H., Bishop J.M., Blackburn E.H. Telomerase extends the lifespan of virus-transformed human cells without net telomere lengthening. Proc Natl Acad Sci U S A 1999, 96:3723-3728. [see comments].
33. Seger Y.R., Garcia-Cao M., Piccinin S., Cunsolo C.L., Doglioni C., Blasco M.A., et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002, 2:401-413.
34. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 2005, 19:2100-2110.
35. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., Fiegler H., Carr P., Von Zglinicki T., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003, 426:194-198.
36. INK4 enrichment and the premature senescence of normal fibroblasts. Oncogene 1998, 16:1113-1123.
37. Jacobs J.J., de Lange T. Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol 2004, 14:2302-2308.
38. Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W., Harley C.B., et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992, 11:1921-1929.
39. Ray F.A., Peabody D.S., Cooper J.L., Cram L.S., Kraemer P.M. SV40 T antigen alone drives karyotype instability that precedes neoplastic transformation of human diploid fibroblasts. J Cell Biochem 1990, 42:13-31.
40. Ducray C., Pommier J.P., Martins L., Boussin F.D., Sabatier L. Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene 1999, 18:4211-4223.
41. Blasco M.A., Lee H.W., Hande M.P., Samper E., Lansdorp P.M., DePinho R.A., et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997, 91:25-34.
42. Gisselsson D., Pettersson L., Hoglund M., Heidenblad M., Gorunova L., Wiegant J., et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci U S A 2000, 97:5357-5362.
43. Murnane J.P., Sabatier L. Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. Bioessays 2004, 26:1164-1174.
44. Rudolph K.L., Millard M., Bosenberg M.W., DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001, 28:155-159.
45. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.-L., Gottlieb G.J., et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999, 97:527-538.
46. Artandi S.E., Chang S., Lee S.L., Alson S., Gottlieb G.J., Chin L., et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000, 406:641-645.
47. O'Sullivan J.N., Bronner M.P., Brentnall T.A., Finley J.C., Shen W.T., Emerson S., et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002, 32:280-284.
48. Romanov S.R., Kozakiewicz B.K., Holst C.R., Stampfer M.R., Haupt L.M., Tlsty T.D. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001, 409:633-637.
49. Wen V.W., Wu K., Baksh S., Hinshelwood R.A., Lock R.B., Clark S.J., et al. Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53-competent immortal endothelial cells. Cancer Res 2006, 66:10691-10700.
50. Stewenius Y., Gorunova L., Jonson T., Larsson N., Hoglund M., Mandahl N., et al. Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci U S A 2005, 102:5541-5546.
51. Gisselsson D., Jonson T., Petersen A., Strombeck B., Dal Cin P., Hoglund M., et al. Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors. Proc Natl Acad Sci U S A 2001, 98:12683-12688.
52. Gisselsson D., Jonson T., Yu C., Martins C., Mandahl N., Wiegant J., et al. Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres. Br J Cancer 2002, 87:202-207.
53. Saunders W.S., Shuster M., Huang X., Gharaibeh B., Enyenihi A.H., Petersen I., et al. Chromosomal instability and cytoskeletal defects in oral cancer cells. Proc Natl Acad Sci U S A 2000, 97:303-308.
54. Chin K., de Solorzano C.O., Knowles D., Jones A., Chou W., Rodriguez E.G., et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004, 36:984-988.
55. Woo R.A., Poon R.Y. Activated oncogenes promote and cooperate with chromosomal instability for neoplastic transformation. Genes Dev 2004, 18:1317-1330.
56. Wei S., Sedivy J.M. Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts. Cancer Res 1999, 59:1539-1543.
57. Shay J.W., Wright W.E. Telomerase: a target for cancer therapeutics. Cancer Cell 2002, 2:257-265.
58. Di Leonardo A., Linke S.P., Clarkin K., Wahl G.M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. Genes Dev 1994, 8:2540-2551.
59. INK4a. Cell 1997, 88:593-602.
60. Serrano M., Blasco M.A. Putting the stress on senescence. Curr Opin Cell Biol 2001, 13:748-753.
61. Sharpless N.E., DePinho R.A. Telomeres, stem cells, senescence, and cancer. J Clin Invest 2004, 113:160-168.
62. Carnero A., Link W., Martinez J.F., Renner O., Castro M.E., Blanco F., et al. Cellular senescence and cancer. Res Adv Cancer 2003, 3:183-198.
63. Chandeck C., Mooi W.J. Oncogene-induced cellular senescence. Adv Anat Pathol 2010, 17:42-48.
64. Braig M., Schmitt C.A. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006, 66:2881-2884.
65. Courtois-Cox S., Jones S.L., Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008, 27:2801-2809.
66. Narlik-Grassow M., Blanco-Aparicio C., Cecilia Y., Perez M., Munoz-Galvan S., Canamero M., et al. Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLOS ONE 2013, 8:e60277.
67. Vergel M., Carnero A. Bypassing cellular senescence by genetic screening tools. Clin Transl Oncol 2010, 12:410-417.
68. Bringold F., Serrano M. Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 2000, 35:317-329.
69. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
70. Ruzankina Y., Asare A., Brown E.J. Replicative stress, stem cells and aging. Mech Ageing Dev 2008, 129:460-466.
71. Kenyon J., Gerson S.L. The role of DNA damage repair in aging of adult stem cells. Nucleic Acids Res 2007, 35:7557-7565.
72. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
73. Lin A.W., Lowe S.W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc Natl Acad Sci U S A 2001, 98:5025-5030.
74. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
75. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
76. Collado M., Serrano M. The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 2006, 6:472-476.
77. Michaloglou C., Vredeveld L.C., Mooi W.J., Peeper D.S. BRAF(E600) in benign and malignant human tumours. Oncogene 2008, 27:877-895.
78. Blanco-Aparicio C., Canamero M., Cecilia Y., Pequeno B., Renner O., Ferrer I., et al. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS ONE 2010, 5:e9305.
79. Gray-Schopfer V.C., Cheong S.C., Chong H., Chow J., Moss T., Abdel-Malek Z.A., et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br J Cancer 2006, 95:496-505.
80. Ewald J.A., Desotelle J.A., Wilding G., Jarrard D.F. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010, 102:1536-1546.
81. Cozzi S.J., Parsons P.G., Ogbourne S.M., Pedley J., Boyle G.M. Induction of senescence in diterpene ester-treated melanoma cells via protein kinase C-dependent hyperactivation of the mitogen-activated protein kinase pathway. Cancer Res 2006, 66:10083-10091.
82. Schwarze S.R., Fu V.X., Desotelle J.A., Kenowski M.L., Jarrard D.F. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia 2005, 7:816-823.
83. Shelton D.N., Chang E., Whittier P.S., Choi D., Funk W.D. Microarray analysis of replicative senescence. Curr Biol 1999, 9:939-945.
84. Schwarze S.R., DePrimo S.E., Grabert L.M., Fu V.X., Brooks J.D., Jarrard D.F. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 2002, 277:14877-14883.
85. de Magalhaes J.P., Chainiaux F., de Longueville F., Mainfroid V., Migeot V., Marcq L., et al. Gene expression and regulation in H2O2-induced premature senescence of human foreskin fibroblasts expressing or not telomerase. Exp Gerontol 2004, 39:1379-1389.
86. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642.
87. Darbro B.W., Schneider G.B., Klingelhutz A.J. Co-regulation of p16INK4A and migratory genes in culture conditions that lead to premature senescence in human keratinocytes. J Invest Dermatol 2005, 125:499-509.
88. Franco N., Lamartine J., Frouin V., Le Minter P., Petat C., Leplat J.J., et al. Low-dose exposure to gamma rays induces specific gene regulations in normal human keratinocytes. Radiat Res 2005, 163:623-635.
89. Alcorta D.A., Xiong Y., Phelps D., Hannon G., Beach D., Barrett J.C. Invovement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci U S A 1996, 93:13742-13747.
90. Stein G.H., Drullinger L.F., Soulard A., Dulic V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol Cell Biol 1999, 19:2109-2117.
91. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
92. Yaswen P., Stampfer M.R. Molecular changes accompanying senescence and immortalization of cultured human mammary epithelial cells. Int J Biochem Cell Biol 2002, 34:1382-1394.
93. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
94. Wynford-Thomas D. p53: guardian of cellular senescence. J Pathol 1996, 180:118-121.
95. Bond J., Haughton M., Blaydes J., Gire V., Wynford-Thomas D., Wyllie F. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. Oncogene 1996, 13:2097-2104.
96. Feldser D.M., Greider C.W. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer Cell 2007, 11:461-469.
97. Ashcroft M., Taya Y., Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000, 20:3224-3233.
98. Blaydes J.P., Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene 1998, 16:3317-3322.
99. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91:649-659.
100. Carnero A., Hudson J.D., Price C.M., Beach D.H. p16INK4A and p19ARF act in overlapping pathways in cellular immortalization. Nat Cell Biol 2000, 2:148-155.
101. Brown J.P., Wei W., Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277:831-834.
102. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
103. Harper J.W., Adami G.R., Wei N., Keyomarsi K., Elledge S.J. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75:805-816.
104. Sherr C.J., Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-1512.
105. Malumbres M., Carnero A. Cell cycle deregulation: a common motif in cancer. Prog Cell Cycle Res 2003, 5:5-18.
106. Carnero A., Beach D.H. Absence of p21WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene 2004, 23:6006-6011.
107. Pantoja C., Serrano M. Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 1999, 18:4974-4982.
108. Ho J.S., Ma W., Mao D.Y., Benchimol S. p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol 2005, 25:7423-7431.
109. Castro M.E., Ferrer I., Cascon A., Guijarro M.V., Lleonart M., Cajal S.R., et al. PPP1CA contributes to the senescence program induced by oncogenic Ras. Carcinogenesis 2008, 29:491-499.
110. Rowland B.D., Denissov S.G., Douma S., Stunnenberg H.G., Bernards R., Peeper D.S. E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell 2002, 2:55-65.
111. Hara E., Tsuri H., Shinozaki S., Oda K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of lifespan in human diploid fibroblasts, TIG-1. Biochem Biophys Res Commun 1991, 179:528-534.
112. Shay J.W., Pereira-Smith O.M., Wright W.E. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991, 196:33-39.
113. Lundberg A.S., Hahn W.C., Gupta P., Weinberg R.A. Genes involved in senescence and immortalization. Curr Opin Cell Biol 2000, 12:705-709.
114. Pavletich N.P. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol 1999, 287:821-828.
115. Chicas A., Wang X., Zhang C., McCurrach M., Zhao Z., Mert O., et al. Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 2010, 17:376-387.
116. Dahiya A., Wong S., Gonzalo S., Gavin M., Dean D.C. Linking the Rb and polycomb pathways. Mol Cell 2001, 8:557-569.
117. Pajalunga D., Mazzola A., Salzano A.M., Biferi M.G., De Luca G., Crescenzi M. Critical requirement for cell cycle inhibitors in sustaining nonproliferative states. J Cell Biol 2007, 176:807-818.
118. Ezhevsky S.A., Nagahara H., Vocero-Akbani A.M., Gius D.R., Wei M.C., Dowdy S.F. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb. Proc Natl Acad Sci U S A 1997, 94:10699-10704.
119. Ezhevsky S.A., Ho A., Becker-Hapak M., Davis P.K., Dowdy S.F. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001, 21:4773-4784.
120. Markey M.P., Angus S.P., Strobeck M.W., Williams S.L., Gunawardena R.W., Aronow B.J., et al. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res 2002, 62:6587-6597.
121. Vernell R., Helin K., Muller H. Identification of target genes of the p16INK4A-pRB-E2F pathway. J Biol Chem 2003, 278:46124-46137.
122. Beausejour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003, 22:4212-4222.
123. Narita M., Narita M., Krizhanovsky V., Nunez S., Chicas A., Hearn S.A., et al. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006, 126:503-514.
124. Zhang H.S., Gavin M., Dahiya A., Postigo A.A., Ma D., Luo R.X., et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000, 101:79-89.
125. Strobeck M.W., Knudsen K.E., Fribourg A.F., DeCristofaro M.F., Weissman B.E., Imbalzano A.N., et al. BRG-1 is required for RB-mediated cell cycle arrest. Proc Natl Acad Sci U S A 2000, 97:7748-7753.
126. Brehm A., Miska E.A., McCance D.J., Reid J.L., Bannister A.J., Kouzarides T. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998, 391:597-601.
127. Young A.P., Longmore G.D. Differences in stability of repressor complexes at promoters underlie distinct roles for Rb family members. Oncogene 2004, 23:814-823.
128. Grewal S.I., Moazed D. Heterochromatin and epigenetic control of gene expression. Science 2003, 301:798-802.
129. Schotta G., Lachner M., Sarma K., Ebert A., Sengupta R., Reuter G., et al. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev 2004, 18:1251-1262.
130. Rea S., Eisenhaber F., O'Carroll D., Strahl B.D., Sun Z.W., Schmid M., et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000, 406:593-599.
131. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carroll D., et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001, 412:561-565.
132. Gonzalo S., Blasco M.A. Role of Rb family in the epigenetic definition of chromatin. Cell Cycle 2005, 4:752-755.
133. Zhang R., Poustovoitov M.V., Ye X., Santos H.A., Chen W., Daganzo S.M., et al. Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 2005, 8:19-30.
134. Ye X., Zerlanko B., Zhang R., Somaiah N., Lipinski M., Salomoni P., et al. Definition of pRB- and p53-dependent and -independent steps in HIRA/ASF1a-mediated formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007, 27:2452-2465.
135. Zhang R., Chen W., Adams P.D. Molecular dissection of formation of senescence-associated heterochromatin foci. Mol Cell Biol 2007, 27:2343-2358.
136. Chandra T., Kirschner K., Thuret J.Y., Pope B.D., Ryba T., Newman S., et al. Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol Cell 2012, 47:203-214.
137. Guerra C., Mijimolle N., Dhawahir A., Dubus P., Barradas M., Serrano M., et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003, 4:111-120.
138. Lazzerini Denchi E., Attwooll C., Pasini D., Helin K. Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 2005, 25:2660-2672.
139. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445:656-660.
140. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445:661-665.
141. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002, 62:1876-1883.
142. Roberson R.S., Kussick S.J., Vallieres E., Chen S.Y., Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005, 65:2795-2803.
143. Jeyapalan J.C., Ferreira M., Sedivy J.M., Herbig U. Accumulation of senescent cells in mitotic tissue of aging primates. Mech Ageing Dev 2007, 128:36-44.
144. Herbig U., Ferreira M., Condel L., Carey D., Sedivy J.M. Cellular senescence in aging primates. Science 2006, 311:1257.
145. Ressler S., Bartkova J., Niederegger H., Bartek J., Scharffetter-Kochanek K., Jansen-Durr P., et al. p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging cell 2006, 5:379-389.
146. Melk A., Schmidt B.M., Takeuchi O., Sawitzki B., Rayner D.C., Halloran P.F. Expression of p16INK4a and other cell cycle regulator and senescence associated genes in aging human kidney. Kidney Int 2004, 65:510-520.
147. INK4A expression in normal human adult and infant tissues. Lab Invest 1999, 79:1137-1143.
148. Molofsky A.V., Slutsky S.G., Joseph N.M., He S., Pardal R., Krishnamurthy J., et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006, 443:448-452.
149. Janzen V., Forkert R., Fleming H.E., Saito Y., Waring M.T., Dombkowski D.M., et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 2006, 443:421-426.
150. Krishnamurthy J., Ramsey M.R., Ligon K.L., Torrice C., Koh A., Bonner-Weir S., et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006, 443:453-457.
151. Krishnamurthy J., Torrice C., Ramsey M.R., Kovalev G.I., Al-Regaiey K., Su L., et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest 2004, 114:1299-1307.
152. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995, 92:9363-9367.
153. Ohtani N., Takahashi A., Mann D.J., Hara E. Cellular senescence: a double-edged sword in the fight against cancer. Exp Dermatol 2012, 21(Suppl. 1):1-4.
154. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., et al. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
155. Baker D.J., Wijshake T., Tchkonia T., LeBrasseur N.K., Childs B.G., van de Sluis B., et al. Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 2011, 479:232-236.
156. Jun J.I., Lau L.F. The matricellular protein CCN1 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol 2010, 12:676-685.
157. Krizhanovsky V., Xue W., Zender L., Yon M., Hernando E., Lowe S.W. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. Cold Spring Harb Symp Quant Biol 2008, 73:513-522.
158. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
159. Lujambio A., Akkari L., Simon J., Grace D., Tschaharganeh D.F., Bolden J.E., et al. Non-cell-autonomous tumor suppression by p53. Cell 2013, 153:449-460.
160. Pitiyage G.N., Slijepcevic P., Gabrani A., Chianea Y.G., Lim K.P., Prime S.S., et al. Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases. J Pathol 2011, 223:604-617.
161. Hoenicke L., Zender L. Immune surveillance of senescent cells - biological significance in cancer- and non-cancer pathologies. Carcinogenesis 2012, 33:1123-1126.
162. Coppe J.P., Rodier F., Patil C.K., Freund A., Desprez P.Y., Campisi J. Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem 2011, 286:36396-36403.
163. Acosta J.C., O'Loghlen A., Banito A., Guijarro M.V., Augert A., Raguz S., et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008, 133:1006-1018.
164. Kuilman T., Michaloglou C., Vredeveld L.C., Douma S., van Doorn R., Desmet C.J., et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008, 133:1019-1031.
165. Novakova Z., Hubackova S., Kosar M., Janderova-Rossmeislova L., Dobrovolna J., Vasicova P., et al. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 2010, 29:273-284.
166. Rodier F., Munoz D.P., Teachenor R., Chu V., Le O., Bhaumik D., et al. DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion. J Cell Sci 2011, 124:68-81.
167. Rodier F., Coppé J.P., Patil C.K., Hoeijmakers W.A., Munoz D.P., Raza S.R., et al. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 2009, 11:973-979.
168. Freund A., Patil C.K., Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 2011, 30:1536-1548.
169. Krtolica A., Parrinello S., Lockett S., Desprez P.Y., Campisi J. Senescent fibroblasts promote epithelial cell growth and tumorigenesis: a link between cancer and aging. Proc Natl Acad Sci U S A 2001, 98:12072-12077.
170. Freund A., Orjalo A.V., Desprez P.Y., Campisi J. Inflammatory networks during cellular senescence: causes and consequences. Trends Mol Med 2010, 16:238-246.
171. Davalos A.R., Coppé J.P., Campisi J., Desprez P.Y. Senescent cells as a source of inflammatory factors for tumor progression. Cancer Metastasis Rev 2010, 29:273-283.
172. Coppé J.P., Desprez P.Y., Krtolica A., Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010, 5:99-118.
173. Coppé J.P., Patil C.K., Rodier F., Sun Y., Munoz D.P., Goldstein J., et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 2008, 6:2853-2868.
174. Coppé J.P., Patil C.K., Rodier F., Krtolica A., Beauséjour C.M., Parrinello S., et al. A human-like senescence-associated secretory phenotype is conserved in mouse cells dependent on physiological oxygen. PLoS ONE 2010, 5:e9188.
175. Rodier F. Detection of the senescence-associated secretory phenotype (SASP). Methods Mol Biol 2013, 965:165-173.
176. Hubackova S., Krejcikova K., Bartek J., Hodny Z. IL1- and TGFbeta-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'. Aging 2012, 4:932-951.
177. Acosta J.C., Banito A., Wuestefeld T., Georgilis A., Janich P., Morton J.P., et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 2013, 15:978-990.
178. Rodier F., Campisi J. Four Faces of cellular senescence. J Cell Biol 2011, 192:547-556.
179. Naylor R.M., Baker D.J., van Deursen J.M. Senescent cells: a novel therapeutic target for aging and age-related diseases. Clin Pharmacol Ther 2013, 93:105-116.
180. Tchkonia T., Zhu Y., van Deursen J., Campisi J., Kirkland J.L. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest 2013, 123:966-972.
181. Parrinello S., Coppé J.P., Krtolica A., Campisi J. Stromal-epithelial interactions in aging and cancer: senescent fibroblasts alter epithelial cell differentiation. J Cell Sci 2005, 118:485-496.
182. Bavik C., Coleman I., Dean J.P., Knudsen B., Plymate S., Nelson P.S. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006, 66:794-802.
183. Liu D., Hornsby P.J. Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 2007, 67:3117-3126.
184. Coppe J.P., Kauser K., Campisi J., Beausejour C.M. Secretion of vascular endothelial growth factor by primary human fibroblasts at senescence. J Biol Chem 2006, 281:29568-29574.
185. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
186. Jackson J.G., Pant V., Li Q., Chang L.L., Quintas-Cardama A., Garza D., et al. p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. Cancer Cell 2012, 21:793-806.
187. Sun Y., Campisi J., Higano C., Beer T.M., Porter P., Coleman I., et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012, 18:1359-1368.
188. Gosselin K., Martien S., Pourtier A., Vercamer C., Ostoich P., Morat L., et al. Senescence-associated oxidative DNA damage promotes the generation of neoplastic cells. Cancer Res 2009, 69:7917-7925.
189. Sherman M.Y., Meng L., Stampfer M., Gabai V.L., Yaglom J.A. Oncogenes induce senescence with incomplete growth arrest and suppress the DNA damage response in immortalized cells. Aging Cell 2011, 10:949-961.
190. Nonet G.H., Stampfer M.R., Chin K., Gray J.W., Collins C.C., Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res 2001, 61:1250-1254.
191. Bazarov A.V., Hines W.C., Mukhopadhyay R., Beliveau A., Melodyev S., Zaslavsky Y., et al. Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes. Cell Cycle 2009, 8:3373-3378.
192. Bosco E.E., Wang Y., Xu H., Zilfou J.T., Knudsen K.E., Aronow B.J., et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest 2007, 117:218-228.
193. Dai C.Y., Enders G.H. p16 INK4a can initiate an autonomous senescence program. Oncogene 2000, 19:1613-1622.
194. Bazarov A.V., Lee W.J., Bazarov I., Bosire M., Hines W.C., Stankovich B., et al. The specific role of pRb in p16 (INK4A) -mediated arrest of normal and malignant human breast cells. Cell Cycle 2012, 11:1008-1013.
195. Viatour P., Somervaille T.C., Venkatasubrahmanyam S., Kogan S., McLaughlin M.E., Weissman I.L., et al. Hematopoietic stem cell quiescence is maintained by compound contributions of the retinoblastoma gene family. Cell Stem Cell 2008, 3:416-428.
196. Jackson J.G., Pereira-Smith O.M. Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells. Mol Cell Biol 2006, 26:2501-2510.
197. Fry D.W., Harvey P.J., Keller P.R., Elliott W.L., Meade M., Trachet E., et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004, 3:1427-1438.
198. Saab R., Bills J.L., Miceli A.P., Anderson C.M., Khoury J.D., Fry D.W., et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 2006, 5:1299-1308.
199. Marzec M., Kasprzycka M., Lai R., Gladden A.B., Wlodarski P., Tomczak E., et al. Mantle cell lymphoma cells express predominantly Cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006, 108:1744-1750.
200. Finn R.S., Dering J., Conklin D., Kalous O., Cohen D.J., Desai A.J., et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res 2009, 11:R77.
201. McClendon A.K., Dean J.L., Rivadeneira D.B., Yu J.E., Reed C.A., Gao E., et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle 2012, 11:2747-2755.
202. Soder A.I., Hoare S.F., Muir S., Going J.J., Parkinson E.K., Keith W.N. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997, 14:1013-1021.
203. Zhang A., Zheng C., Lindvall C., Hou M., Ekedahl J., Lewensohn R., et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res 2000, 60:6230-6235.
204. Zhang A., Zheng C., Hou M., Lindvall C., Wallin K.L., Angstrom T., et al. Amplification of the telomerase reverse transcriptase (hTERT) gene in cervical carcinomas. Genes Chromosomes Cancer 2002, 34:269-275.
205. Takuma Y., Nouso K., Kobayashi Y., Nakamura S., Tanaka H., Matsumoto E., et al. Telomerase reverse transcriptase gene amplification in hepatocellular carcinoma. J Gastroenterol Hepatol 2004, 19:1300-1304.
206. Pirker C., Holzmann K., Spiegl-Kreinecker S., Elbling L., Thallinger C., Pehamberger H., et al. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res 2003, 13:483-492.
207. Zhao Y., Wang S., Popova E.Y., Grigoryev S.A., Zhu J. Rearrangement of upstream sequences of the hTERT gene during cellular immortalization. Genes Chromosomes Cancer 2009, 48:963-974.
208. Codd V., Nelson C.P., Albrecht E., Mangino M., Deelen J., Buxton J.L., et al. Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet 2013, 45:422-427.
209. Bojesen S.E., Pooley K.A., Johnatty S.E., Beesley J., Michailidou K., Tyrer J.P., et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 2013, 45:371-384.
210. Melin B.S., Nordfjall K., Andersson U., Roos G. hTERT cancer risk genotypes are associated with telomere length. Genet Epidemiol 2012, 36:368-372.
211. Kote-Jarai Z., Saunders E.J., Leongamornlert D.A., Tymrakiewicz M., Dadaev T., Jugurnauth-Little S., et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 2013, 22:2520-2528.
212. Atkinson S.P., Hoare S.F., Glasspool R.M., Keith W.N. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters. Cancer Res 2005, 65:7585-7590.
213. Soder A.I., Going J.J., Kaye S.B., Keith W.N. Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization. Oncogene 1998, 16:979-983.
214. Plumb J.A., Bilsland A., Kakani R., Zhao J., Glasspool R.M., Knox R.J., et al. Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954. Oncogene 2001, 20:7797-7803.
215. Bilsland A.E., Anderson C.J., Fletcher-Monaghan A.J., McGregor F., Evans T.R., Ganly I., et al. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene 2003, 22:370-380.
216. Zhao J.Q., Glasspool R.M., Hoare S.F., Bilsland A., Szatmari I., Keith W.N. Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. Neoplasia 2000, 2:531-539.
217. Zhao J., Bilsland A., Jackson K., Keith W.N. MDM2 negatively regulates the human telomerase RNA gene promoter. BMC Cancer 2005, 5:6.
218. Bilsland A.E., Stevenson K., Atkinson S., Kolch W., Keith W.N. Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3. Cancer Res 2006, 66:1363-1370.
219. Wu K.J., Grandori C., Amacker M., Simon-Vermot N., Polack A., Lingner J., et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999, 21:220-224.
220. Wick M., Zubov D., Hagen G. Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 1999, 232:97-106.
221. Horikawa I., Cable P.L., Afshari C., Barrett J.C. Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res 1999, 59:826-830.
222. Anderson C.J., Hoare S.F., Ashcroft M., Bilsland A.E., Keith W.N. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms. Oncogene 2006, 25:61-69.
223. Maida Y., Kyo S., Kanaya T., Wang Z., Yatabe N., Tanaka M., et al. Direct activation of telomerase by EGF through Ets-mediated transactivation of TERT via MAP kinase signaling pathway. Oncogene 2002, 21:4071-4079.
224. Huang F.W., Hodis E., Xu M.J., Kryukov G.V., Chin L., Garraway L.A. Highly recurrent TERT promoter mutations in human melanoma. Science 2013, 339:957-959.
225. Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A., et al. TERT promoter mutations in familial and sporadic melanoma. Science 2013, 339:959-961.
226. Crowe D.L., Nguyen D.C. Rb and E2F-1 regulate telomerase activity in human cancer cells. Biochim Biophys Acta 2001, 1518:1-6.
227. Chou C.K., Lee D.F., Sun H.L., Li L.Y., Lin C.Y., Huang W.C., et al. The suppression of MAD1 by AKT-mediated phosphorylation activates MAD1 target genes transcription. Mol Carcinog 2009, 48:1048-1058.
228. Wu S., Hultquist A., Hydbring P., Cetinkaya C., Oberg F., Larsson L.G. TGF-beta enforces senescence in Myc-transformed hematopoietic tumor cells through induction of Mad1 and repression of Myc activity. Exp Cell Res 2009, 315:3099-3111.
229. Beyne-Rauzy O., Recher C., Dastugue N., Demur C., Pottier G., Laurent G., et al. Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. Oncogene 2004, 23:7507-7516.
230. Henderson Y.C., Breau R.L., Liu T.J., Clayman G.L. Telomerase activity in head and neck tumors after introduction of wild-type p53, p21, p16, and E2F-1 genes by means of recombinant adenovirus. Head Neck 2000, 22:347-354.
231. Hoffmeyer K., Raggioli A., Rudloff S., Anton R., Hierholzer A., Del Valle I., et al. Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells. Science 2012, 336:1549-1554.
232. Zhang Y., Toh L., Lau P., Wang X. Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/beta-catenin pathway in human cancer. J Biol Chem 2012, 287:32494-32511.
233. Jaitner S., Reiche J.A., Schaffauer A.J., Hiendlmeyer E., Herbst H., Brabletz T., et al. Human telomerase reverse transcriptase (hTERT) is a target gene of beta-catenin in human colorectal tumors. Cell Cycle 2012, 11:3331-3338.
234. Bilsland A.E., Hoare S., Stevenson K., Plumb J., Gomez-Roman N., Cairney C., et al. Dynamic telomerase gene suppression via network effects of GSK3 inhibition. PLoS ONE 2009, 4:e6459.
235. Wang J., Xie L.Y., Allan S., Beach D., Hannon G.J. Myc activates telomerase. Genes Dev 1998, 12:1769-1774.
236. Harley C.B. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8:167-179.
237. Bryan T.M., Englezou A., Gupta J., Bacchetti S., Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995, 14:4240-4248.
238. Bryan T.M., Englezou A., Dalla-Pozza L., Dunham M.A., Reddel R.R. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997, 3:1271-1274.
239. Chang S., Khoo C.M., Naylor M.L., Maser R.S., DePinho R.A. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 2003, 17:88-100.
240. Hu J., Hwang S.S., Liesa M., Gan B., Sahin E., Jaskelioff M., et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012, 148:651-663.
241. Shay J.W., Wright W.E. Telomeres and telomerase in normal and cancer stem cells. FEBS Lett 2010, 584:3819-3825.
242. Sprouse A.A., Steding C.E., Herbert B.S. Pharmaceutical regulation of telomerase and its clinical potential. J Cell Mol Med 2012, 16:1-7.
243. Podlevsky J.D., Chen J.J. It all comes together at the ends: telomerase structure, function, and biogenesis. Mutat Res 2012, 730:3-11.
244. Zhang X., Mar V., Zhou W., Harrington L., Robinson M. Telomere shortening and apoptosisin telomerase-inhibited human tumor cells. Genes Dev 1999, 13:2388-2399.
245. Tauchi T., Nakajima A., Sashida G., Shimamoto T., Ohyashiki J.H., Abe K., et al. Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. Clin Cancer Res 2002, 8:3341-3347.
246. Delhommeau F., Thierry A., Feneux D., Lauret E., Leclercq E., Courtier M.H., et al. Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 2002, 21:8262-8271.
247. Nakajima A., Tauchi T., Sashida G., Sumi M., Abe K., Yamamoto K., et al. Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy. Leukemia 2003, 17:560-567.
248. Roth A., Vercauteren S., Sutherland H.J., Lansdorp P.M. Telomerase is limiting the growth of acute myeloid leukemia cells. Leukemia 2003, 17:2410-2417.
249. Feng J., Funk W.D., Wang S.-S., Weinrich S.L., Avilion A.A., Chiu C.-P., et al. The RNA component of human telomerase. Science 1995, 269:1236-1241.
250. Norton J.C., Piatyszek M.A., Wright W.E., Shay J.W., Corey D.R. Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 1996, 14:615-619.
251. Kondo S., Tanaka Y., Kondo Y., Hitomi M., Barnett G.H., Ishizaka Y., et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J 1998, 12:801-811.
252. Pitts A.E., Corey D.R. Inhibition of human telomerase by 2'-O-methyl-RNA. Proc Natl Acad Sci U S A 1998, 95:11549-11554.
253. Herbert B., Pitts A.E., Baker S.I., Hamilton S.E., Wright W.E., Shay J.W., et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci U S A 1999, 96:14276-14281.
254. Herbert B.S., Pongracz K., Shay J.W., Gryaznov S.M. Oligonucleotide N3' → P5' phosphoramidates as efficient telomerase inhibitors. Oncogene 2002, 21:638-642.
255. Corey D.R. Telomerase inhibition, oligonucleotides, and clinical trials. Oncogene 2002, 21:631-637.
256. Asai A., Oshima Y., Yamamoto Y., Uochi T.A., Kusaka H., Akinaga S., et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res 2003, 63:3931-3939.
257. Wang E.S., Wu K., Chin A.C., Chen-Kiang S., Pongracz K., Gryaznov S., et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004, 103:258-266.
258. Akiyama M., Hideshima T., Shammas M.A., Hayashi T., Hamasaki M., Tai Y.T., et al. Effects of oligonucleotide N3' → P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 2003, 63:6187-6194.
259. Djojosubroto M.W., Chin A.C., Go N., Schaetzlein S., Manns M.P., Gryaznov S., et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. Hepatology 2005, 42:1127-1136.
260. Herbert B.S., Gellert G.C., Hochreiter A., Pongracz K., Wright W.E., Zielinska D., et al. Lipid modification of GRN163, an N3' → P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 2005, 24:5262-5268.
261. Tokcaer-Keskin Z., Dikmen Z.G., Ayaloglu-Butun F., Gultekin S., Gryaznov S.M., Akcali K.C. The effect of telomerase template antagonist GRN163L on bone-marrow-derived rat mesenchymal stem cells is reversible and associated with altered expression of cyclin d1, cdk4 and cdk6. Stem Cell Rev 2010, 6:224-233.
262. Gellert G.C., Dikmen Z.G., Wright W.E., Gryaznov S., Shay J.W. Effects of a novel telomerase inhibitor, GRN163L, in human breast cancer. Breast Cancer Res Treat 2006, 96:73-81.
263. Hochreiter A.E., Xiao H., Goldblatt E.M., Gryaznov S.M., Miller K.D., Badve S., et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 2006, 12:3184-3192.
264. Dikmen Z.G., Gellert G.C., Jackson S., Gryaznov S., Tressler R., Dogan P., et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005, 65:7866-7873.
265. Shammas M.A., Koley H., Bertheau R.C., Neri P., Fulciniti M., Tassone P., et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 2008, 22:1410-1418.
266. Jackson S.R., Zhu C.H., Paulson V., Watkins L., Dikmen Z.G., Gryaznov S.M., et al. Antiadhesive effects of GRN163L - an oligonucleotide N3'→P5' thio-phosphoramidate targeting telomerase. Cancer Res 2007, 67:1121-1129.
267. Mender I., Senturk S., Ozgunes N., Akcali K.C., Kletsas D., Gryaznov S., et al. Imetelstat (a telomerase antagonist) exerts offtarget effects on the cytoskeleton. Int J Oncol 2013, 42:1709-1715.
268. Kraemer K., Fuessel S., Schmidt U., Kotzsch M., Schwenzer B., Wirth M.P., et al. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003, 9:3794-3800. [see comment].
269. Folini M., Brambilla C., Villa R., Gandellini P., Vignati S., Paduano F., et al. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells. Eur J Cancer 2005, 41:624-634.
270. Yuan Z., Mei H.D. Inhibition of telomerase activity with hTERT antisense increases the effect of CDDP-induced apoptosis in myeloid leukemia. Hematol J 2002, 3:201-205.
271. Kosciolek B.A., Kalantidis K., Tabler M., Rowley P.T. Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2003, 2:209-216.
272. Kanazawa Y., Ohkawa K., Ueda K., Mita E., Takehara T., Sasaki Y., et al. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells. Biochem Biophys Res Commun 1996, 225:570-576.
273. Folini M., Colella G., Villa R., Lualdi S., Daidone M.G., Zaffaroni N. Inhibition of telomerase activity by a hammerhead ribozyme targeting the RNA component of telomerase in human melanoma cells. J Invest Dermatol 2000, 114:259-267.
274. Yokoyama Y., Takahashi Y., Shinohara A., Wan X., Takahashi S., Niwa K., et al. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity. Biochem Biophys Res Commun 2000, 273:316-321.
275. Ludwig A., Saretzki G., Holm P.S., Tiemann F., Lorenz M., Emrich T., et al. Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 2001, 61:3053-3061.
276. Shammas M.A., Koley H., Batchu R.B., Bertheau R.C., Protopopov A., Munshi N.C., et al. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 2005, 4:24.
277. Masutomi K., Possemato R., Wong J.M., Currier J.L., Tothova Z., Manola J.B., et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005, 102:8222-8227.
278. Yuan J., Yang B.M., Zhong Z.H., Shats I., Milyavsky M., Rotter V., et al. Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase. Oncogene 2009, 28:2678-2689.
279. Li S., Rosenberg J.E., Donjacour A.A., Botchkina I.L., Hom Y.K., Cunha G.R., et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telomerase RNA and anti-telomerase short-interfering RNA. Cancer Res 2004, 64:4833-4840.
280. Smith L.L., Coller H.A., Roberts J.M. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003, 5:474-479.
281. Stewart S.A., Hahn W.C., O'Connor B.F., Banner E.N., Lundberg A.S., Modha P., et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2002, 99:12606-12611.
282. Naasani I., Seimiya H., Yamori T., Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 1999, 59:4004-4011.
283. Hayakawa N., Nozawa K., Ogawa A., Kato N., Yoshida K., Akamatsu K., et al. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Biochemistry 1999, 38:11501-11507.
284. Damm K., Hemmann U., Garin-Chesa P., Hauel N., Kauffmann I., Priepke H., et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001, 20:6958-6968.
285. Kleideiter E., Piotrowska K., Klotz U. Screening of telomerase inhibitors. Methods Mol Biol 2007, 405:167-180.
286. Wong L.H., Unciti-Broceta A., Spitzer M., White R., Tyers M., Harrington L. A yeast chemical genetic screen identifies inhibitors of human telomerase. Chem Biol 2013, 20:333-340.
287. Seimiya H., Oh-hara T., Suzuki T., Naasani I., Shimazaki T., Tsuchiya K., et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 2002, 1:657-665.
288. Pascolo E., Wenz C., Lingner J., Hauel N., Priepke H., Kauffmann I., et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 2002, 277:15566-15572.
289. El-Daly H., Kull M., Zimmermann S., Pantic M., Waller C.F., Martens U.M. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005, 105:1742-1749.
290. Sengupta S., Peterson T.R., Sabatini D.M. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010, 40:310-322.
291. Jiang B.H., Liu L.Z. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Updat 2008, 11:63-76.
292. Bu X., Jia F., Wang W., Guo X., Wu M., Wei L. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. BMC Cancer 2007, 7:208.
293. Sundin T., Peffley D.M., Gauthier D., Hentosh P. The isoprenoid perillyl alcohol inhibits telomerase activity in prostate cancer cells. Biochimie 2012, 94:2639-2648.
294. Sundin T., Peffley D.M., Hentosh P. Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin. Mol Cell Biochem 2013, 375:97-104.
295. Zhao Y.M., Zhou Q., Xu Y., Lai X.Y., Huang H. Antiproliferative effect of rapamycin on human T-cell leukemia cell line Jurkat by cell cycle arrest and telomerase inhibition. Acta Pharmacol Sin 2008, 29:481-488.
296. Zhou C., Gehrig P.A., Whang Y.E., Boggess J.F. Rapamycin inhibits telomerase activity by decreasing the hTERT mRNA level in endometrial cancer cells. Mol Cancer Ther 2003, 2:789-795.
297. Sundin T., Hentosh P. InTERTesting association between telomerase, mTOR and phytochemicals. Expert Rev Mol Med 2012, 14:e8.
298. Filaci G., Fravega M., Setti M., Traverso P., Millo E., Fenoglio D., et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 2006, 107:1505-1512.
299. Gannage M., Abel M., Michallet A.S., Delluc S., Lambert M., Giraudier S., et al. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005, 174:8210-8218.
300. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
301. Vonderheide R.H. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002, 21:674-679.
302. Nair S.K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J.S., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000, 6:1011-1017.
303. Cortez-Gonzalez X., Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med 2007, 5:12.
304. Danet-Desnoyers G.A., Luongo J.L., Bonnet D.A., Domchek S.M., Vonderheide R.H. Telomerase vaccination has no detectable effect on SCID-repopulating and colony-forming activities in the bone marrow of cancer patients. Exp Hematol 2005, 33:1275-1280.
305. Holysz H., Lipinska N., Paszel-Jaworska A., Rubis B. Telomerase as a useful target in cancer fighting-the breast cancer case. Tumour Biol 2013, 34:1371-1380.
306. Elson C.E., Peffley D.M., Hentosh P., Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 1999, 221:294-311.
307. Jahangir T., Sultana S. Perillyl alcohol protects against Fe-NTA-induced nephrotoxicity and early tumor promotional events in rat experimental model. Evid Based Complement Alternat Med 2007, 4:439-445.
308. Liston B.W., Nines R., Carlton P.S., Gupta A., Aziz R., Frankel W., et al. Perillyl alcohol as a chemopreventive agent in N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Cancer Res 2003, 63:2399-2403.
309. Chaudhary S.C., Alam M.S., Siddiqui M.S., Athar M. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 2009, 179:145-153.
310. Cho H.Y., Wang W., Jhaveri N., Torres S., Tseng J., Leong M.N., et al. Perillyl alcohol for the treatment of temozolomide-resistant gliomas. Mol Cancer Ther 2012, 11:2462-2472.
311. Farazuddin M., Sharma B., Khan A.A., Joshi B., Owais M. Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles. Int J Nanomed 2012, 7:35-47.
312. Lebedeva I.V., Su Z.Z., Vozhilla N., Chatman L., Sarkar D., Dent P., et al. Chemoprevention by perillyl alcohol coupled with viral gene therapy reduces pancreatic cancer pathogenesis. Mol Cancer Ther 2008, 7:2042-2050.
313. Mo H., Elson C.E. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 2004, 229:567-585.
314. Peffley D.M., Sharma C., Hentosh P., Buechler R.D. Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells. Arch Biochem Biophys 2007, 465:266-273.
315. Jagadeesh S., Kyo S., Banerjee P.P. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res 2006, 66:2107-2115.
316. Ouchi H., Ishiguro H., Ikeda N., Hori M., Kubota Y., Uemura H. Genistein induces cell growth inhibition in prostate cancer through the suppression of telomerase activity. Int J Urol 2005, 12:73-80.
317. Chau M.N., El Touny L.H., Jagadeesh S., Banerjee P.P. Physiologically achievable concentrations of genistein enhance telomerase activity in prostate cancer cells via the activation of STAT3. Carcinogenesis 2007, 28:2282-2290.
318. Tuntiwechapikul W., Taka T., Songsomboon C., Kaewtunjai N., Imsumran A., Makonkawkeyoon L., et al. Ginger extract inhibits human telomerase reverse transcriptase and c-Myc expression in A549 lung cancer cells. J Med Food 2010, 13:1347-1354.
319. Khan N., Afaq F., Khusro F.H., Adhami V.M., Suh Y., Mukhtar H. Dual inhibition of PI3K/AKT and mTOR signaling in human non-small cell lung cancer cells by a dietary flavonoid fisetin. Int J Cancer 2011, 130:1695-1705.
320. Syed D.N., Adhami V.M., Khan M.I., Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem 2012, 13:995-1001.
321. Seguin J., Brulle L., Boyer R., Lu Y.M., Ramos Romano M., Touil Y.S., et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm, 2013, 444:146-154.
322. Khaw A.K., Hande M.P., Kalthur G. Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells. J Cell Biochem 2012, 114:1257-1270.
323. Mukherjee Nee Chakraborty S., Ghosh U., Bhattacharyya N.P., Bhattacharya R.K., Dey S., Roy M. Curcumin-induced apoptosis in human leukemia cell HL-60 is associated with inhibition of telomerase activity. Mol Cell Biochem 2007, 297:31-39.
324. Singh M., Singh N. Molecular mechanism of curcumin induced cytotoxicity in human cervical carcinoma cells. Mol Cell Biochem 2009, 325:107-119.
325. Lee J.H., Chung I.K. Curcumin inhibits nuclear localization of telomerase by dissociating the Hsp90 co-chaperone p23 from hTERT. Cancer Lett 2010, 290:76-86.
326. Beevers C.S., Chen L., Liu L., Luo Y., Webster N.J., Huang S. Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res 2009, 69:1000-1008.
327. Chakravarti N., Kadara H., Yoon D.J., Shay J.W., Myers J.N., Lotan D., et al. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prev Res (Phila) 2010, 3:331-338.
328. Shehzad A., Lee Y.S. Molecular mechanisms of curcumin action: signal transduction. Biofactors 2013, 39:27-36.
329. Hasima N., Aggarwal B.B. Cancer-linked targets modulated by curcumin. Int J Biochem Mol Biol 2012, 3:328-351.
330. Ramachandran C., Fonseca H.B., Jhabvala P., Escalon E.A., Melnick S.J. Curcumin inhibits telomerase activity through human telomerase reverse transcritpase in MCF-7 breast cancer cell line. Cancer Lett 2002, 184:1-6.
331. Hsin I.L., Sheu G.T., Chen H.H., Chiu L.Y., Wang H.D., Chan H.W., et al. N-acetyl cysteine mitigates curcumin-mediated telomerase inhibition through rescuing of Sp1 reduction in A549 cells. Mutat Res 2010, 688:72-77.
332. Fuggetta M.P., Lanzilli G., Tricarico M., Cottarelli A., Falchetti R., Ravagnan G., et al. Effect of resveratrol on proliferation and telomerase activity of human colon cancer cells in vitro. J Exp Clin Cancer Res 2006, 25:189-193.
333. Lanzilli G., Fuggetta M.P., Tricarico M., Cottarelli A., Serafino A., Falchetti R., et al. Resveratrol down-regulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol 2006, 28:641-648.
334. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009, 125:1-8.
335. Singh B.N., Shankar S., Srivastava R.K. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem Pharmacol 2011, 82:1807-1821.
336. Lin S.C., Li W.C., Shih J.W., Hong K.F., Pan Y.R., Lin J.J. The tea polyphenols EGCG and EGC repress mRNA expression of human telomerase reverse transcriptase (hTERT) in carcinoma cells. Cancer Lett 2006, 236:80-88.
337. Meeran S.M., Patel S.N., Chan T.H., Tollefsbol T.O. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res (Phila) 2011, 4:1243-1254.
338. Naasani I., Oh-Hashi F., Oh-Hara T., Feng W.Y., Johnston J., Chan K., et al. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 2003, 63:824-830.
339. Wang X., Hao M.W., Dong K., Lin F., Ren J.H., Zhang H.Z. Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharm Res 2009, 32:1263-1269.
340. Marconett C.N., Sundar S.N., Tseng M., Tin A.S., Tran K.Q., Mahuron K.M., et al. Indole-3-carbinol downregulation of telomerase gene expression requires the inhibition of estrogen receptor-alpha and Sp1 transcription factor interactions within the hTERT promoter and mediates the G1 cell cycle arrest of human breast cancer cells. Carcinogenesis 2011, 32:1315-1323.
341. Moon D.O., Kang S.H., Kim K.C., Kim M.O., Choi Y.H., Kim G.Y. Sulforaphane decreases viability and telomerase activity in hepatocellular carcinoma Hep3B cells through the reactive oxygen species-dependent pathway. Cancer Lett 2010, 295:260-266.
342. Warabi K., Hamada T., Nakao Y., Matsunaga S., Hirota H., van Soest R.W., et al. Axinelloside A, an unprecedented highly sulfated lipopolysaccharide inhibiting telomerase, from the marine sponge, Axinella infundibula. J Am Chem Soc 2005, 127:13262-13270.
343. Tauchi T., Shin-ya K., Sashida G., Sumi M., Okabe S., Ohyashiki J.H., et al. Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. Oncogene 2006, 25:5719-5725.
344. Tauchi T., Shin-Ya K., Sashida G., Sumi M., Nakajima A., Shimamoto T., et al. Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. Oncogene 2003, 22:5338-5347.
345. Kim M.Y., Vankayalapati H., Shin-Ya K., Wierzba K., Hurley L.H. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. J Am Chem Soc 2002, 124:2098-2099.
346. Binz N., Shalaby T., Rivera P., Shin-ya K., Grotzer M.A. Telomerase inhibition, telomere shortening, cell growth suppression and induction of apoptosis by telomestatin in childhood neuroblastoma cells. Eur J Cancer 2005, 41:2873-2881.
347. Deeley J., Bertram A., Pattenden G. Novel polyoxazole-based cyclopeptides from Streptomyces sp. total synthesis of the cyclopeptide YM-216391 and synthetic studies towards telomestatin. Org Biomol Chem 2008, 6:1994-2010.
348. Doi T., Yoshida M., Shin-ya K., Takahashi T. Total synthesis of (R)-telomestatin. Org Lett 2006, 8:4165-4167.
349. Seimiya H., Muramatsu Y., Ohishi T., Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005, 7:25-37.
350. Smith S., Giriat I., Schmitt A., de Lange T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 1998, 282:1484-1487. [see comments].
351. Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A., et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009, 461:614-620.
352. Zahler A.M., Williamson J.R., Cech T.R., Prescott D.M. Inhibition of telomerase by G-quartet DNA structures. Nature 1991, 350:718-720.
353. Tang J., Kan Z.Y., Yao Y., Wang Q., Hao Y.H., Tan Z. G-quadruplex preferentially forms at the very 3' end of vertebrate telomeric DNA. Nucleic Acids Res 2008, 36:1200-1208.
354. Mergny J.L., Lacroix L., Teulade-Fichou M.P., Hounsou C., Guittat L., Hoarau M., et al. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc Natl Acad Sci U S A 2001, 98:3062-3067.
355. Izbicka E., Nishioka D., Marcell V., Raymond E., Davidson K.K., Lawrence R.A., et al. Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des 1999, 14:355-365.
356. Gowan S.M., Harrison J.R., Patterson L., Valenti M., Read M.A., Neidle S., et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 2002, 61:1154-1162.
357. Shin-ya K., Wierzba K., Matsuo K., Ohtani T., Yamada Y., Furihata K., et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc 2001, 123:1262-1263.
358. Gowan S.M., Heald R., Stevens M.F., Kelland L.R. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol 2001, 60:981-988.
359. Cookson J.C., Dai F., Smith V., Heald R.A., Laughton C.A., Stevens M.F., et al. Pharmacodynamics of the G-quadruplex-stabilizing telomerase inhibitor 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) in vitro: activity in human tumor cells correlates with telomere length and can be enhanced, or antagonized, with cytotoxic agents. Mol Pharmacol 2005, 68:1551-1558.
360. Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H., Anderson K.C., et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004, 10:770-776.
361. Sumi M., Tauchi T., Sashida G., Nakajima A., Gotoh A., Shin-Ya K., et al. A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. Int J Oncol 2004, 24:1481-1487.
362. Chen Y., Dokmanovic M., Stein W.D., Ardecky R.J., Roninson I.B. Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cells. Cancer Res 2006, 66:8749-8761.
363. Moreno-Aspitia A., Perez E.A. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009, 31:1619-1640.
364. Varna M., Lehmann-Che J., Turpin E., Marangoni E., El-Bouchtaoui M., Jeanne M., et al. p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer 2009, 124:991-997.
365. Cairney C.J., Bilsland A.E., Evans T.R., Roffey J., Bennett D.C., Narita M., et al. Cancer cell senescence: a new frontier in drug development. Drug Discov Today 2012, 17:269-276.
366. Lahtela J., Corson L.B., Hemmes A., Brauer M.J., Koopal S., Lee J., et al. A high-content cellular senescence screen identifies candidate tumor suppressors, including EPHA3. Cell Cycle 2013, 12:625-634.
367. Ewald J.A., Peters N., Desotelle J.A., Hoffmann F.M., Jarrard D.F. A high-throughput method to identify novel senescence-inducing compounds. J Biomol Screen 2009, 14:853-858.
368. Samaila D., Toy B.J., Wang R.C., Elegbede J.A. Monoterpenes enhanced the sensitivity of head and neck cancer cells to radiation treatment in vitro. Anticancer Res 2004, 24:3089-3095.
369. da Fonseca C.O., Schwartsmann G., Fischer J., Nagel J., Futuro D., Quirico-Santos T., et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol 2008, 70:259-266. discussion 66-7.
370. da Fonseca C.O., Simao M., Lins I.R., Caetano R.O., Futuro D., Quirico-Santos T. Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma. J Cancer Res Clin Oncol 2011, 137:287-293.
371. Morgan-Meadows S., Dubey S., Gould M., Tutsch K., Marnocha R., Arzoomanin R., et al. Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemother Pharmacol 2003, 52:361-366.
372. Stratton S.P., Alberts D.S., Einspahr J.G., Sagerman P.M., Warneke J.A., Curiel-Lewandrowski C., et al. A phase 2a study of topical perillyl alcohol cream for chemoprevention of skin cancer. Cancer Prev Res (Phila) 2010, 3:160-169.
373. Aoki H., Takada Y., Kondo S., Sawaya R., Aggarwal B.B., Kondo Y. Evidence that curcumin suppresses the growth of malignant gliomas in vitro and in vivo through induction of autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways. Mol Pharmacol 2007, 72:29-39.
374. Phillips J.M., Clark C., Herman-Ferdinandez L., Moore-Medlin T., Rong X., Gill J.R., et al. Curcumin inhibits skin squamous cell carcinoma tumor growth in vivo. Otolaryngol Head Neck Surg 2011, 145:58-63.
375. Royt M., Mukherjee S., Sarkar R., Biswas J. Curcumin sensitizes chemotherapeutic drugs via modulation of PKC, telomerase, NF-kappaB and HDAC in breast cancer. Ther Deliv 2011, 2:1275-1293.
376. Seo J.H., Jeong K.J., Oh W.J., Sul H.J., Sohn J.S., Kim Y.K., et al. Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin. Cancer Lett 2010, 288:50-56.
377. Bayet-Robert M., Kwiatkowski F., Leheurteur M., Gachon F., Planchat E., Abrial C., et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 2010, 9:8-14.
378. Carroll R.E., Benya R.V., Turgeon D.K., Vareed S., Neuman M., Rodriguez L., et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila) 2011, 4:354-364.
379. Dhillon N., Aggarwal B.B., Newman R.A., Wolff R.A., Kunnumakkara A.B., Abbruzzese J.L., et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 2008, 14:4491-4499.
380. Kanai M., Yoshimura K., Asada M., Imaizumi A., Suzuki C., Matsumoto S., et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 2011, 68:157-164.
381. Leontieva O.V., Paszkiewicz G., Demidenko Z.N., Blagosklonny M.V. Resveratrol potentiates rapamycin to prevent hyperinsulinemia and obesity in male mice on high fat diet. Cell Death Dis 2013, 4:e472.
382. Um H.J., Bae J.H., Park J.W., Suh H., Jeong N.Y., Yoo Y.H., et al. Differential effects of resveratrol and novel resveratrol derivative, HS-1793, on endoplasmic reticulum stress-mediated apoptosis and Akt inactivation. Int J Oncol 2010, 36:1007-1013.
383. Colin D., Limagne E., Jeanningros S., Jacquel A., Lizard G., Athias A., et al. Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev Res (Phila) 2011, 4:1095-1106.
384. Juan M.E., Alfaras I., Planas J.M. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res 2012, 65:584-591.
385. Cottart C.H., Nivet-Antoine V., Laguillier-Morizot C., Beaudeux J.L. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010, 54:7-16.
386. Nguyen A.V., Martinez M., Stamos M.J., Moyer M.P., Planutis K., Hope C., et al. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag Res 2009, 1:25-37.
387. Patel K.R., Brown V.A., Jones D.J., Britton R.G., Hemingway D., Miller A.S., et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010, 70:7392-7399.
388. Van Aller G.S., Carson J.D., Tang W., Peng H., Zhao L., Copeland R.A., et al. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor. Biochem Biophys Res Commun 2011, 406:194-199.
389. Gupta S., Hastak K., Afaq F., Ahmad N., Mukhtar H. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 2004, 23:2507-2522.
390. Tang S.N., Fu J., Shankar S., Srivastava R.K. EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS ONE 2012, 7:e31067.
391. Khan N., Afaq F., Saleem M., Ahmad N., Mukhtar H. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 2006, 66:2500-2505.
392. McLarty J., Bigelow R.L., Smith M., Elmajian D., Ankem M., Cardelli J.A. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila) 2009, 2:673-682.
393. Zou C., Liu H., Feugang J.M., Hao Z., Chow H.H., Garcia F. Green tea compound in chemoprevention of cervical cancer. Int J Gynecol Cancer 2010, 20:617-624.
394. Wu H., Xin Y., Xu C., Xiao Y. Capecitabine combined with (-)-epigallocatechin-3-gallate inhibits angiogenesis and tumor growth in nude mice with gastric cancer xenografts. Exp Ther Med 2012, 3:650-654.
395. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006, 66:1234-1240.
396. Shanafelt T.D., Call T.G., Zent C.S., LaPlant B., Bowen D.A., Roos M., et al. Phase I trial of daily oral polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009, 27:3808-3814.
397. Shanafelt T.D., Call T.G., Zent C.S., Leis J.F., Laplant B., Bowen D.A., et al. Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Chemioterapia 2013, 119:363-370.
398. Peffley D., Hentosh P. Plant-derived isoprenoids mediate regulation of mTOR signaling in tumor cells. Natural compounds as inducers of cell death 2012, Springer Publishing. M. Diederich (Ed.).
399. Lazarevic B., Boezelijn G., Diep L.M., Kvernrod K., Ogren O., Ramberg H., et al. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer 2011, 63:889-898.
400. Roger L., Jones R.E., Heppel N.H., Williams G.T., Sampson J.R., Baird D.M. Extensive telomere erosion in the initiation of colorectal adenomas and its association with chromosomal instability. J Natl Cancer Inst 2013, 105:1202-1211.
401. Chou W.C., Hawkins A.L., Barrett J.F., Griffin C.A., Dang C.V. Arsenic inhibition of telomerase transcription leads to genetic instability. J Clin Investig 2001, 108:1541-1547.
402. Lu R., Pal J., Buon L., Nanjappa P., Shi J., Fulciniti M., et al. Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. Oncogene 2014, 33:1495-1505.
403. Lu Y., Wu Y., Feng X., Shen R., Wang J.H., Fallahi M., et al. CDK4 deficiency promotes genomic instability and enhances Myc-driven lymphomagenesis. J Clin Investig 2014, 124:1672-1684.
404. Hughes B.T., Sidorova J., Swanger J., Monnat R.J., Clurman B.E. Essential role for Cdk2 inhibitory phosphorylation during replication stress revealed by a human Cdk2 knockin mutation. Proc Natl Acad Sci U S A 2013, 110:8954-8959.
405. Ma Y., Yuan X., Wyatt W.R., Pomerening J.R. Expression of constitutively active CDK1 stabilizes APC-Cdh1 substrates and potentiates premature spindle assembly and checkpoint function in G1 cells. PLoS ONE 2012, 7:e33835.
406. Xu N., Hegarat N., Black E.J., Scott M.T., Hochegger H., Gillespie D.A. Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. J Cell Biol 2010, 190:297-305.
407. Nelson A.C., Lyons T.R., Young C.D., Hansen K.C., Anderson S.M., Holt J.T. AKT regulates BRCA1 stability in response to hormone signaling. Mol Cell Endocrinol 2010, 319:129-142.
408. Plo I., Lopez B. AKT1 represses gene conversion induced by different genotoxic stresses and induces supernumerary centrosomes and aneuploidy in hamster ovary cells. Oncogene 2009, 28:2231-2237.
409. Nam H.J., Chae S., Jang S.H., Cho H., Lee J.H. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis 2010, 31:1531-1540.
410. Ghosh A., Saginc G., Leow S.C., Khattar E., Shin E.M., Yan T.D., et al. Telomerase directly regulates NF-kappaB-dependent transcription. Nat Cell Biol 2012, 14:1270-1281.
411. Beck S., Jin X., Sohn Y.W., Kim J.K., Kim S.H., Yin J., et al. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells 2011, 31:9-15.
412. Jiang Y., Chen C., Chen S.M., Wang Y.Q., Xu Y., Wang Y., et al. Telomerase reverse transcriptase promotes the proliferation of human laryngeal carcinoma cells through activation of the activator protein 1. Oncol Lett 2013, 6:75-80.
413. Kraemer K., Schmidt U., Fuessel S., Herr A., Wirth M.P., Meye A. Microarray analyses in bladder cancer cells: inhibition of hTERT expression down-regulates EGFR. Int J Cancer 2006, 119:1276-1284.
414. Dong S., Zhang X.C., Cheng H., Zhu J.Q., Chen Z.H., Zhang Y.F., et al. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Chemother Pharmacol 2012, 70:707-716.
415. Grabinski N., Ewald F., Hofmann B.T., Staufer K., Schumacher U., Nashan B., et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012, 11:85.
416. Hou X., Zhao M., Wang T., Zhang G. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncol Rep 2014, 31:1175-1182.
417. Mao C.Q., Xiong M.H., Liu Y., Shen S., Du X.J., Yang X.Z., et al. Synthetic lethal therapy for KRAS mutant non-small-cell lung carcinoma with nanoparticle-mediated CDK4 siRNA delivery. Mol Ther J Am Soc Gene Ther 2014, 22:964-973.
418. Witkiewicz A.K., Cox D.W., Rivadeneira D., Ertel A.E., Fortina P., Schwartz G.F., et al. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene 2013, 33:3980-3991.
419. Rea K., Sensi M., Anichini A., Canevari S., Tomassetti A. EGFR/MEK/ERK/CDK5-dependent integrin-independent FAK phosphorylated on serine 732 contributes to microtubule depolymerization and mitosis in tumor cells. Cell Death Dis 2013, 4:e815.
420. Xie W., Wang H., He Y., Li D., Gong L., Zhang Y. CDK5 and its activator P35 in normal pituitary and in pituitary adenomas: relationship to VEGF expression. Int J Biol Sci 2014, 10:192-199.
421. Held J.M., Britton D.J., Scott G.K., Lee E.L., Schilling B., Baldwin M.A., et al. Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305. Mol Cancer Res 2012, 10:1120-1132.
422. Kunter I., Erdal E., Nart D., Yilmaz F., Karademir S., Sagol O., et al. Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. Oncol Rep 2014, 31:573-580.
423. He Z., Deng Y., Li W., Chen Y., Xing S., Zhao X., et al. Overexpression of PTEN suppresses lipopolysaccharide-induced lung fibroblast proliferation, differentiation and collagen secretion through inhibition of the PI3-K-Akt-GSK3beta pathway. Cell Biosci 2014, 4:2.
424. Chen X., Qin Q., Zhang W., Zhang Y., Zheng H., Liu C., et al. Activation of the PI3K-AKT-mTOR signaling pathway promotes DEHP-induced Hep3B cell proliferation. Food Chem Toxicol 2013, 59:325-333.
425. Bodo J., Zhao X., Sharma A., Hill B.T., Portell C.A., Lannutti B.J., et al. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Br J Haematol 2013, 163:72-80.
426. Garbers C., Kuck F., Aparicio-Siegmund S., Konzak K., Kessenbrock M., Sommerfeld A., et al. Cellular senescence or EGFR signaling induces Interleukin 6 (IL-6) receptor expression controlled by mammalian target of rapamycin (mTOR). Cell Cycle 2013, 12:3421-3432.
427. Yuan H., Lu J., Xiao J., Upadhyay G., Umans R., Kallakury B., et al. PPARdelta induces estrogen receptor-positive mammary neoplasia through an inflammatory and metabolic phenotype linked to mTOR activation. Cancer Res 2013, 73:4349-4361.
428. Handschick K., Beuerlein K., Jurida L., Bartkuhn M., Muller H., Soelch J., et al. Cyclin-dependent kinase 6 is a chromatin-bound cofactor for NF-kappaB-dependent gene expression. Mol Cell 2014, 53:193-208.
429. Du J., Wei N., Guan T., Xu H., An J., Pritchard K.A., et al. Inhibition of CDKS by roscovitine suppressed LPS-induced *NO production through inhibiting NFkappaB activation and BH4 biosynthesis in macrophages. Am J Physiol Cell Physiol 2009, 297:C742-C749.
430. Berberich N., Uhl B., Joore J., Schmerwitz U.K., Mayer B.A., Reichel C.A., et al. Roscovitine blocks leukocyte extravasation by inhibition of cyclin-dependent kinases 5 and 9. Br J Pharmacol 2011, 163:1086-1098.
431. Dong Y.L., Kabir S.M., Lee E.S., Son D.S. CXCR2-driven ovarian cancer progression involves upregulation of proinflammatory chemokines by potentiating NF-kappaB activation via EGFR-transactivated Akt signaling. PLOS ONE 2013, 8:e83789.
432. Smith D.A., Kiba A., Zong Y., Witte O.N. Interleukin-6 and oncostatin-M synergize with the PI3K/AKT pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol Cancer Res 2013, 11:1159-1165.
433. Wang Y., Wang W., Wang L., Wang X., Xia J. Regulatory mechanisms of interleukin-8 production induced by tumour necrosis factor-alpha in human hepatocellular carcinoma cells. J Cell Mol Med 2012, 16:496-506.
434. Zhang Y., Wang L., Zhang M., Jin M., Bai C., Wang X. Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol 2012, 227:35-43.
435. Xue Y., Li L., Zhang D., Wu K., Guo P., Zeng J., et al. Telomerase suppression initiates PML-dependent p53 activation to inhibit bladder cancer cell growth. Oncol Rep 2010, 24:1551-1559.
436. Wall M., Poortinga G., Stanley K.L., Lindemann R.K., Bots M., Chan C.J., et al. The mTORC1 inhibitor everolimus prevents and treats Emu-Myc lymphoma by restoring oncogene-induced senescence. Cancer Discov 2013, 3:82-95.
437. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005, 120:747-759.
438. Gogolin S., Ehemann V., Becker G., Brueckner L.M., Dreidax D., Bannert S., et al. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage. Cell Cycle 2013, 12:1091-1104.
439. Rader J., Russell M.R., Hart L.S., Nakazawa M.S., Belcastro L.T., Martinez D., et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res 2013, 19:6173-6182.
440. Dai L., Liu Y., Liu J., Wen X., Xu Z., Wang Z., et al. A novel cyclinE/cyclinA-CDK inhibitor targets p27(Kip1) degradation, cell cycle progression and cell survival: implications in cancer therapy. Cancer Lett 2013, 333:103-112.
441. De Leon G., Cavino M., D'Angelo M., Krucher N.A. PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cells. Int J Oncol 2010, 36:1269-1275.
442. Zhang C., Lundgren K., Yan Z., Arango M.E., Price S., Huber A., et al. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Mol Cancer Ther 2008, 7:818-828.
443. Jiao P., Zhou Y.S., Yang J.X., Zhao Y.L., Liu Q.Q., Yuan C., et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. Mol Cell Biochem 2013, 382:217-224.
444. Xu X., Lu Z., Qiang W., Vidimar V., Kong B., Kim J.J., et al. Inactivation of AKT induces cellular senescence in uterine leiomyoma. Endocrinology 2014, 155:1510-1519.
445. Cotrim C.Z., Fabris V., Doria M.L., Lindberg K., Gustafsson J.A., Amado F., et al. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene 2013, 32:2390-2402.
446. Li C., Liu V.W., Chan D.W., Yao K.M., Ngan H.Y. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells. Int J Gynecol Cancer 2012, 22:15-22.
447. Mukherjee S., Bhattacharya R.K., Roy M. Targeting protein kinase C (PKC) and telomerase by phenethyl isothiocyanate (PEITC) sensitizes PC-3 cells towards chemotherapeutic drug-induced apoptosis. J Environ Pathol Toxicol Oncol 2009, 28:269-282.
448. Wang T., Xue Y., Wang M., Sun Q. Silencing of the hTERT gene through RNA interference induces apoptosis via bax/bcl-2 in human glioma cells. Oncol Rep 2012, 28:1153-1158.
449. Ge J., Liu Y., Li Q., Guo X., Gu L., Ma Z.G., et al. Resveratrol induces apoptosis and autophagy in T-cell acute lymphoblastic leukemia cells by inhibiting Akt/mTOR and activating p38-MAPK. Biomed Environ Sci 2013, 26:902-911.
450. Zhang X.H., Cheng Y., Shin J.Y., Kim J.O., Oh J.E., Kang J.H. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS. Cancer Biol Ther 2013, 14:597-605.
451. Zolnierczyk J.D., Blonski J.Z., Robak T., Kilianska Z.M., Wesierska-Gadek J. Roscovitine triggers apoptosis in B-cell chronic lymphocytic leukemia cells with similar efficiency as combinations of conventional purine analogs with cyclophosphamide. Ann N Y Acad Sci 2009, 1171:124-131.
452. Cassinelli G., Zuco V., Gatti L., Lanzi C., Zaffaroni N., Colombo D., et al. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells. Curr Med Chem 2013, 20:1923-1945.
453. Bagheri S., Nosrati M., Li S., Fong S., Torabian S., Rangel J., et al. Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A 2006, 103:11306-11311.
454. Liu L.L., Long Z.J., Wang L.X., Zheng F.M., Fang Z.G., Yan M., et al. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol Cancer Res 2013, 11:1326-1336.
455. Zanuy M., Ramos-Montoya A., Villacanas O., Canela N., Miranda A., Aguilar E., et al. Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle. Metabolomics 2012, 8:454-464.
456. Yalcin A., Clem B.F., Simmons A., Lane A., Nelson K., Clem A.L., et al. Nuclear targeting of 6-phosphofructo-2-kinase (PFKFB3) increases proliferation via cyclin-dependent kinases. J Biol Chem 2009, 284:24223-24232.
457. Liu Z., Zhang Y.Y., Zhang Q.W., Zhao S.R., Wu C.Z., Cheng X., et al. 3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway. Anticancer Drugs 2014, 25:447-455.
458. Liu P.P., Liao J., Tang Z.J., Wu W.J., Yang J., Zeng Z.L., et al. Metabolic regulation of cancer cell side population by glucose through activation of the Akt pathway. Cell Death Differ 2014, 21:124-135.
459. Gershon T.R., Crowther A.J., Tikunov A., Garcia I., Annis R., Yuan H., et al. Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer Metab 2013, 1:2.
460. Polivka J., Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther 2014, 142:164-175.
461. Wang Y., Sparwasser T., Figlin R., Kim H.L. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition. Cancer Res 2014, 74:2217-2228.
462. Noh K.H., Kim B.W., Song K.H., Cho H., Lee Y.H., Kim J.H., et al. Nanog signaling in cancer promotes stem-like phenotype and immune evasion. J Clin Investig 2012, 122:4077-4093.
463. Webb L.M., Vigorito E., Wymann M.P., Hirsch E., Turner M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J Immunol 2005, 175:2783-2787.
464. Hemon P., Jean-Louis F., Ramgolam K., Brignone C., Viguier M., Bachelez H., et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. J Immunol 2011, 186:5173-5183.
465. Pallini R., Pierconti F., Falchetti M.L., D'Arcangelo D., Fernandez E., Maira G., et al. Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells. J Neurosurg 2001, 94:961-971.
466. Karar J., Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011, 4:51.
467. Chen Z., Zhang Y., Jia C., Wang Y., Lai P., Zhou X., et al. mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression. Oncogene 2014, 33:4548-4557.
468. Kollmann K., Heller G., Schneckenleithner C., Warsch W., Scheicher R., Ott R.G., et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 2013, 24:167-181.
469. Abedin Z.R., Ma Z., Reddy E.P. Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Cell Cycle 2010, 9:2456-2463.
470. Warfel N.A., Dolloff N.G., Dicker D.T., Malysz J., El-Deiry W.S. CDK1 stabilizes HIF-1alpha via direct phosphorylation of Ser668 to promote tumor growth. Cell Cycle 2013, 12:3689-3701.
471. Liebl J., Krystof V., Vereb G., Takacs L., Strnad M., Pechan P., et al. Anti-angiogenic effects of purine inhibitors of cyclin dependent kinases. Angiogenesis 2011, 14:281-291.
472. Chen P.C., Peng J.R., Huang L., Li W.X., Wang W.Z., Cui Z.Q., et al. Overexpression of human telomerase reverse transcriptase promotes the motility and invasiveness of HepG2 cells in vitro. Oncol Rep 2013, 30:1157-1164.
473. Yu S.T., Chen L., Wang H.J., Tang X.D., Fang D.C., Yang S.M. hTERT promotes the invasion of telomerase-negative tumor cells in vitro. Int J Oncol 2009, 35:329-336.
474. Zong H., Yin B., Zhou H., Cai D., Ma B., Xiang Y. Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition. Mol Biol Rep 2014, 41:4507-4512.
475. Lin G., Gai R., Chen Z., Wang Y., Liao S., Dong R., et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-beta1. Eur J Pharmacol 2014, 729:45-53.
476. Liu F., Korc M. Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther 2012, 11:2138-2148.
477. Wu A., Wu B., Guo J., Luo W., Wu D., Yang H., et al. Elevated expression of CDK4 in lung cancer. J Transl Med 2011, 9:38.
478. Strock C.J., Park J.I., Nakakura E.K., Bova G.S., Isaacs J.T., Ball D.W., et al. Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006, 66:7509-7515.
479. Huang C., Rajfur Z., Yousefi N., Chen Z., Jacobson K., Ginsberg M.H. Talin phosphorylation by Cdk5 regulates Smurf1-mediated talin head ubiquitylation and cell migration. Nat Cell Biol 2009, 11:624-630.
480. Barrette K., Van Kelst S., Wouters J., Marasigan V., Fieuws S., Agostinis P., et al. Epithelial-mesenchymal transition during invasion of cutaneous squamous cell carcinoma is paralleled by AKT activation. Br J Dermatol 2014, 171:1014-1021.
481. Falchetti M.L., Mongiardi M.P., Fiorenzo P., Petrucci G., Pierconti F., D'Agnano I., et al. Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts. Int J Cancer 2008, 122:1236-1242.
482. Liu Z., Li Q., Li K., Chen L., Li W., Hou M., et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 2013, 32:4203-4213.
483. Saito K., Matsumoto S., Yasui H., Devasahayam N., Subramanian S., Munasinghe J.P., et al. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS ONE 2012, 7:e49456.
484. Al-Ansari M.M., Hendrayani S.F., Shehata A.I., Aboussekhra A. p16(INK4A) represses the paracrine tumor-promoting effects of breast stromal fibroblasts. Oncogene 2013, 32:2356-2364.
485. Chatzistamou I., Dioufa N., Trimis G., Sklavounou A., Kittas C., Kiaris H., et al. p21/waf1 and smooth-muscle actin alpha expression in stromal fibroblasts of oral cancers. Cell Oncol 2011, 34:483-488.
486. Capparelli C., Guido C., Whitaker-Menezes D., Bonuccelli G., Balliet R., Pestell T.G., et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 2012, 11:2285-2302.
487. Subramaniam K.S., Tham S.T., Mohamed Z., Woo Y.L., Mat Adenan N.A., Chung I. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLOS ONE 2013, 8:e68923.
488. Lin B.Q., Zeng Z.Y., Yang S.S., Zhuang C.W. Dietary restriction suppresses tumor growth, reduces angiogenesis, and improves tumor microenvironment in human non-small-cell lung cancer xenografts. Lung Cancer 2013, 79:111-117.
489. Rosich L., Saborit-Villarroya I., Lopez-Guerra M., Xargay-Torrent S., Montraveta A., Aymerich M., et al. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica 2013, 98:1739-1747.
490. Wu X., Smavadati S., Nordfjall K., Karlsson K., Qvarnstrom F., Simonsson M., et al. Telomerase antagonist imetelstat inhibits esophageal cancer cell growth and increases radiation-induced DNA breaks. Biochim Biophys Acta 2012, 1823:2130-2135.
491. Uziel O., Reshef H., Ravid A., Fabian I., Halperin D., Ram R., et al. Oxidative stress causes telomere damage in Fanconi anaemia cells - a possible predisposition for malignant transformation. Br J Haematol 2008, 142:82-93.
492. Kim Y.M., Yang S., Xu W., Li S., Yang X. Continuous in vitro exposure to low-dose genistein induces genomic instability in breast epithelial cells. Cancer Genet Cytogenet 2008, 186:78-84.
493. Pugalendhi P., Manoharan S., Panjamurthy K., Balakrishnan S., Nirmal M.R. Antigenotoxic effect of genistein against 7,12-dimethylbenz[a]anthracene induced genotoxicity in bone marrow cells of female Wistar rats. Pharmacol Rep 2009, 61:296-303.
494. Chan N.L., Wang H., Wang Y., Leung H.Y., Leung L.K. Polycyclic aromatic hydrocarbon-induced CYP1B1 activity is suppressed by perillyl alcohol in MCF-7 cells. Toxicol Appl Pharmacol 2006, 213:98-104.
495. Ogiwara H., Ui A., Shiotani B., Zou L., Yasui A., Kohno T. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Carcinogenesis 2013, 34:2486-2497.
496. Thomas P., Wang Y.J., Zhong J.H., Kosaraju S., O'Callaghan N.J., Zhou X.F., et al. Grape seed polyphenols and curcumin reduce genomic instability events in a transgenic mouse model for Alzheimer's disease. Mutat Res 2009, 661:25-34.
497. Durgo K., Kostic S., Gradiski K., Komes D., Osmak M., Franekic J. Genotoxic effects of green tea extract on human laryngeal carcinoma cells in vitro. Arh Hig Rada Toksikol 2011, 62:139-146.
498. Tobi S.E., Gilbert M., Paul N., McMillan T.J. The green tea polyphenol, epigallocatechin-3-gallate, protects against the oxidative cellular and genotoxic damage of UVA radiation. Int J Cancer 2002, 102:439-444.
499. Chiyomaru T., Yamamura S., Fukuhara S., Hidaka H., Majid S., Saini S., et al. Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer. PLOS ONE 2013, 8:e58929.
500. Nakamura H., Wang Y., Kurita T., Adomat H., Cunha G.R., Wang Y. Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer. PLoS ONE 2011, 6:e20034.
501. Fischer Jde S., Liao L., Carvalho P.C., Barbosa V.C., Domont G.B., Carvalho Mda G., et al. Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol. J Proteomics 2010, 73:1018-1027.
502. Logan J.E., Mostofizadeh N., Desai A.J., Von Euw E., Conklin D., Konkankit V., et al. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res 2013, 33:2997-3004.
503. Feldmann G., Mishra A., Bisht S., Karikari C., Garrido-Laguna I., Rasheed Z., et al. Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 2011, 12:598-609.
504. Ono M., Higuchi T., Takeshima M., Chen C., Nakano S. Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. Anticancer Res 2013, 33:1861-1866.
505. Cai X.Z., Wang J., Li X.D., Wang G.L., Liu F.N., Cheng M.S., et al. Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther 2009, 8:1360-1368.
506. Lim Y.C., Cha Y.Y. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of EGFR/ERK pathway and cyclin B1/CDK1 complex. J Surg Oncol 2011, 104:776-780.
507. Ma Y.C., Li C., Gao F., Xu Y., Jiang Z.B., Liu J.X., et al. Epigallocatechin gallate inhibits the growth of human lung cancer by directly targeting the EGFR signaling pathway. Oncol Rep 2014, 31:1343-1349.
508. Khan A.Q., Khan R., Rehman M.U., Lateef A., Tahir M., Ali F., et al. Soy isoflavones (daidzein & genistein) inhibit 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced cutaneous inflammation via modulation of COX-2 and NF-kappaB in Swiss albino mice. Toxicology 2012, 302:266-274.
509. D'Alessandro T., Prasain J., Benton M.R., Botting N., Moore R., Darley-Usmar V., et al. Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J Nutr 2003, 133:3773S-3777S.
510. Hall J.M., Korach K.S. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Mol Carcinog 2013, 52:715-725.
511. Magkouta S., Stathopoulos G.T., Psallidas I., Papapetropoulos A., Kolisis F.N., Roussos C., et al. Protective effects of mastic oil from Pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma. Nutr Cancer 2009, 61:640-648.
512. Vaughan R.A., Garcia-Smith R., Dorsey J., Griffith J.K., Bisoffi M., Trujillo K.A. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int J Cancer 2013, 133:2504-2510.
513. Killian P.H., Kronski E., Michalik K.M., Barbieri O., Astigiano S., Sommerhoff C.P., et al. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. Carcinogenesis 2012, 33:2507-2519.
514. Nonn L., Duong D., Peehl D.M. Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis 2007, 28:1188-1196.
515. Hardtner C., Multhoff G., Falk W., Radons J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol 2012, 684:36-43.
516. Hoffmann J., Junker H., Schmieder A., Venz S., Brandt R., Multhoff G., et al. EGCG downregulates IL-1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem Pharmacol 2011, 82:1153-1162.
517. Zhang Z., Wang C.Z., Du G.J., Qi L.W., Calway T., He T.C., et al. Genistein induces G2/M cell cycle arrest and apoptosis via ATM/p53-dependent pathway in human colon cancer cells. Int J Oncol 2013, 43:289-296.
518. Li Y., Chen H., Hardy T.M., Tollefsbol T.O. Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein. PLOS ONE 2013, 8:e54369.
519. Majid S., Kikuno N., Nelles J., Noonan E., Tanaka Y., Kawamoto K., et al. Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res 2008, 68:2736-2744.
520. Yuri T., Danbara N., Tsujita-Kyutoku M., Kiyozuka Y., Senzaki H., Shikata N., et al. Perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2004, 84:251-260.
521. Konecny G.E., Winterhoff B., Kolarova T., Qi J., Manivong K., Dering J., et al. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Clin Cancer Res 2011, 17:1591-1602.
522. Desai B.M., Villanueva J., Nguyen T.T., Lioni M., Xiao M., Kong J., et al. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLOS ONE 2013, 8:e59588.
523. Mosieniak G., Adamowicz M., Alster O., Jaskowiak H., Szczepankiewicz A.A., Wilczynski G.M., et al. Curcumin induces permanent growth arrest of human colon cancer cells: link between senescence and autophagy. Mech Ageing Dev 2012, 133:444-455.
524. Abusnina A., Keravis T., Yougbare I., Bronner C., Lugnier C. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res 2011, 55:1677-1689.
525. Zhang X., Min K.W., Wimalasena J., Baek S.J. Cyclin D1 degradation and p21 induction contribute to growth inhibition of colorectal cancer cells induced by epigallocatechin-3-gallate. J Cancer Res Clin Oncol 2012, 138:2051-2060.
526. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int J Oncol 2012, 41:353-361.
527. Phan V., Walters J., Brownlow B., Elbayoumi T. Enhanced cytotoxicity of optimized liposomal genistein via specific induction of apoptosis in breast, ovarian and prostate carcinomas. J Drug Target 2013, 21:1001-1011.
528. Prietsch R.F., Monte L.G., da Silva F.A., Beira F.T., Del Pino F.A., Campos V.F., et al. Genistein induces apoptosis and autophagy in human breast MCF-7 cells by modulating the expression of proapoptotic factors and oxidative stress enzymes. Mol Cell Biochem 2014, 390:235-242.
529. Yeruva L., Pierre K.J., Elegbede A., Wang R.C., Carper S.W. Perillyl alcohol and perillic acid induced cell cycle arrest and apoptosis in non small cell lung cancer cells. Cancer Lett 2007, 257:216-226.
530. Gomez-Contreras P.C., Hernandez-Flores G., Ortiz-Lazareno P.C., Del Toro-Arreola S., Delgado-Rizo V., Lerma-Diaz J.M., et al. In vitro induction of apoptosis in U937 cells by perillyl alcohol with sensitization by pentoxifylline: increased BCL-2 and BAX protein expression. Chemotherapy 2006, 52:308-315.
531. Chiron D., Martin P., Di Liberto M., Huang X., Ely S., Lannutti B.J., et al. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell Cycle 2013, 12:1892-1900.
532. Fu W., Ma L., Chu B., Wang X., Bui M.M., Gemmer J., et al. The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther 2011, 10:1018-1027.
533. Yu L.L., Wu J.G., Dai N., Yu H.G., Si J.M. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-kappaB transcription factor. Oncol Rep 2011, 26:1197-1203.
534. Cao A., Li Q., Yin P., Dong Y., Shi H., Wang L., et al. Curcumin induces apoptosis in human gastric carcinoma AGS cells and colon carcinoma HT-29 cells through mitochondrial dysfunction and endoplasmic reticulum stress. Apoptosis 2013, 18:1391-1402.
535. Li J.J., Gu Q.H., Li M., Yang H.P., Cao L.M., Hu C.P. Role of Ku70 and Bax in epigallocatechin-3-gallate-induced apoptosis of A549 cells in vivo. Oncol Lett 2013, 5:101-106.
536. Manohar M., Fatima I., Saxena R., Chandra V., Sankhwar P.L., Dwivedi A. (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation. J Nutr Biochem 2013, 24:940-947.
537. Boros L.G., Bassilian S., Lim S., Lee W.N. Genistein inhibits nonoxidative ribose synthesis in MIA pancreatic adenocarcinoma cells: a new mechanism of controlling tumor growth. Pancreas 2001, 22:1-7.
538. Bayet-Robert M., Morvan D. Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLOS ONE 2013, 8:e57971.
539. Moreira L., Araujo I., Costa T., Correia-Branco A., Faria A., Martel F., et al. Quercetin and epigallocatechin gallate inhibit glucose uptake and metabolism by breast cancer cells by an estrogen receptor-independent mechanism. Exp Cell Res 2013, 319:1784-1795.
540. Relat J., Blancafort A., Oliveras G., Cufi S., Haro D., Marrero P.F., et al. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer 2012, 12:280.
541. Guo T.L., Chi R.P., Hernandez D.M., Auttachoat W., Zheng J.F. Decreased 7,12-dimethylbenz[a]anthracene-induced carcinogenesis coincides with the induction of antitumor immunities in adult female B6C3F1 mice pretreated with genistein. Carcinogenesis 2007, 28:2560-2566.
542. Bhattacharyya S., Md Sakib Hossain D., Mohanty S., Sankar Sen G., Chattopadhyay S., Banerjee S., et al. Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts. Cell Mol Immunol 2010, 7:306-315.
543. Chang Y.F., Chuang H.Y., Hsu C.H., Liu R.S., Gambhir S.S., Hwang J.J. Immunomodulation of curcumin on adoptive therapy with T cell functional imaging in mice. Cancer Prev Res 2012, 5:444-452.
544. Mantena S.K., Roy A.M., Katiyar S.K. Epigallocatechin-3-gallate inhibits photocarcinogenesis through inhibition of angiogenic factors and activation of CD8+ T cells in tumors. Photochem Photobiol 2005, 81:1174-1179.
545. Kawai K., Tsuno N.H., Kitayama J., Okaji Y., Yazawa K., Asakage M., et al. Epigallocatechin gallate attenuates adhesion and migration of CD8+ T cells by binding to CD11b. J Allergy Clin Immunol 2004, 113:1211-1217.
546. Kang T.H., Lee J.H., Song C.K., Han H.D., Shin B.C., Pai S.I., et al. Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res 2007, 67:802-811.
547. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A 1993, 90:2690-2694.
548. Guo Y., Wang S., Hoot D.R., Clinton S.K. Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem 2007, 18:408-417.
549. Kang X., Jin S., Zhang Q. Antitumor and antiangiogenic activity of soy phytoestrogen on 7,12-dimethylbenz[alpha]anthracene-induced mammary tumors following ovariectomy in Sprague-Dawley rats. J Food Sci 2009, 74:H237-H242.
550. Loutrari H., Hatziapostolou M., Skouridou V., Papadimitriou E., Roussos C., Kolisis F.N., et al. Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 2004, 311:568-575.
551. Arbiser J.L., Klauber N., Rohan R., van Leeuwen R., Huang M.T., Fisher C., et al. Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998, 4:376-383.
552. Jung Y.D., Ellis L.M. Inhibition of tumour invasion and angiogenesis by epigallocatechin gallate (EGCG), a major component of green tea. Int J Exp Pathol 2001, 82:309-316.
553. Deng P.B., Hu C.P., Xiong Z., Yang H.P., Li Y.Y. Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2. Chin J Nat Med 2013, 11:245-253.
554. El Touny L.H., Banerjee P.P. Identification of a biphasic role for genistein in the regulation of prostate cancer growth and metastasis. Cancer Res 2009, 69:3695-3703.
555. Nakamura H., Wang Y., Xue H., Romanish M.T., Mager D.L., Helgason C.D., et al. Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer. Prostate 2013, 73:1747-1760.
556. Yu D., Shin H.S., Lee Y.S., Lee D., Kim S., Lee Y.C. Genistein attenuates cancer stem cell characteristics in gastric cancer through the downregulation of Gli1. Oncol Rep 2014, 31:673-678.
557. Cheng T.S., Chen W.C., Lin Y.Y., Tsai C.H., Liao C.I., Shyu H.Y., et al. Curcumin-targeting pericellular serine protease matriptase role in suppression of prostate cancer cell invasion, tumor growth, and metastasis. Cancer Prev Res 2013, 6:495-505.
558. Soung Y.H., Chung J. Curcumin inhibition of the functional interaction between integrin alpha6beta4 and the epidermal growth factor receptor. Mol Cancer Ther 2011, 10:883-891.
559. Deb G., Thakur V.S., Limaye A.M., Gupta S. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells. Mol Carcinog 2014.
560. Maruyama T., Murata S., Nakayama K., Sano N., Ogawa K., Nowatari T., et al. (-)-Epigallocatechin-3-gallate suppresses liver metastasis of human colorectal cancer. Oncol Rep 2014, 31:625-633.
561. Takahashi A., Watanabe T., Mondal A., Suzuki K., Kurusu-Kanno M., Li Z., et al. Mechanism-based inhibition of cancer metastasis with (-)-epigallocatechin gallate. Biochem Biophys Res Commun 2014, 443:1-6.
562. Lou D., Wang B., Wang Y., Cao Y. Selective killing of cancer stem cells by a novel dual-targeting strategy. Med Hypotheses 2012, 79:430-432.
563. Dai W., Wang F., He L., Lin C., Wu S., Chen P., et al. Genistein inhibits hepatocellular carcinoma cell migration by reversing the epithelial-mesenchymal transition: Partial mediation by the transcription factor NFAT. Mol Carcinog 2015, 54:301-311.
564. Johnson A.J., Yeh Y.Y., Smith L.L., Wagner A.J., Hessler J., Gupta S., et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Leukemia 2012, 26:2554-2557.
565. Vishvakarma N.K., Kumar A., Singh S.M. Role of curcumin-dependent modulation of tumor microenvironment of a murine T cell lymphoma in altered regulation of tumor cell survival. Toxicol Appl Pharmacol 2011, 252:298-306.
566. Ghosh A.K., Kay N.E., Secreto C.R., Shanafelt T.D. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clinical Cancer Res 2009, 15:1250-1258.
567. Suzuki Y., Isemura M. Binding interaction between (-)-epigallocatechin gallate causes impaired spreading of cancer cells on fibrinogen. Biomed Res 2013, 34:301-308.